跳至主要内容
临床试验/NCT03356236
NCT03356236招募中不适用

A Multicenter, Prospective Cohort Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

Yue Han17 个研究点 分布在 1 个国家目标入组 828 人开始时间: 2018年4月17日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
828
试验地点
17
主要终点
Progression-free survival (PFS)

研究概览

简要总结

To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation

详细描述

A multicenter, prospective cohort study investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation,to evaluate the efficacy and safety

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years ≤ Age ≤ 75 years, both male and female
  • Patients are diagnosed with HCC via examination of tissues according to Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma (Version 2017) by NHFPC (National Health and Family Planning Commission of the People's Republic of China) and/or HCC imaging criteria of American Association for the Study of Liver Diseases (AASLD) for the diagnosis of HCC;
  • Radiographic testing shows cancer cells have been eliminated after four weeks of Local Ablation;Complete Response (CR): Dynamic contrast-enhanced CT scans and follow-up MR images show low-density area of Hepatocellular Carcinoma and no enhancement during the arterial phase of contrast-enhanced CT; also patients with 0.5-1 cm beyond the limits of the tumor margins (considered as safe surgical margins) are eligible;
  • According to contrast-enhanced CT and MRI, with solitary tumor smaller than 5 cm in diameter; with multiple tumors (no more than 3 masses), the largest dimension is less than 3 cm;
  • Patients are eligible if Hemoglobin (Hb) count ≥90g/L, platelets count (PLT) ≥60×109/L, absolute neutrophil count (ANC) count >1.0×109/L, prothrombin activity (PTA)>50%, serum creatinine is less than 1.5 times ULN (Upper Limit of Normal) and total bilirubin (TBIL) <51.3μmol/L (3 mg/dL);
  • ECOG score of 0-1;
  • Liver function is Child - Pugh grade A or B.
  • History of TACE for treatment of HCC is less than or equal to twice -
  • The patients are volunteered for the study, sign informed consent form and cooperate with Investigator to collect data.

排除标准

  • Radiographic testing shows cancer cells have not been eliminated after four weeks of Local Ablation;
  • The occurrence of embolism occurs in large blood vessels on liver, patients with extrahepatic metastatic of HCC or liver transplantation;
  • Patients who are about to receive or already received chemotherapy or molecular targeted therapy;
  • Patients who are about to receive TACE treatment for HCC;
  • Patients without previous treatment of Huaier granules.
  • History of diabetes;
  • HCC patients with uncontrollable ascites at the beginning of enrollment of the study or are very likely to have ascites during the next four weeks at the time of enrollment; patients with hepatic encephalopathy or upper gastrointestinal bleeding;
  • Patients have basic diseases including severe cardiopulmonary insufficiency, renal insufficiency, or severe mental illness;
  • Patients with other infectious disease (excluding viral hepatitis)
  • Patients who cannot take oral medication;
  • Conditions that are considered not suitable for this study investigators.

结局指标

主要结局

Progression-free survival (PFS)

时间窗: 96 weeks

PFS was defined as the duration of time from start of treatment to time of disease progression.

次要结局

  • Recurrence-Free Survival (RFS)(96 weeks)
  • Overall Survival (OS)(Time from baseline to death (up to 96 weeks))
  • Change From Baseline in Quality of Life (QOL)(24, 48, 72, 96 weeks)
  • Time to recurrence (TTR)(Time from baseline to relapse (up to 96 weeks))
  • severity of Adverse events (AE)(96 weeks)
  • Incidence rate of Adverse events (AE)(96 weeks)

研究者

发起方
Yue Han
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yue Han

Professor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (17)

Loading locations...

相似试验